{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:11:03Z","timestamp":1781111463403,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"DOI":"10.1186\/s13643-024-02746-3","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T11:49:20Z","timestamp":1737978560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The impact of sodium-glucose cotransporter-2 inhibitors on the incidence, therapy, and outcomes of fournier gangrene: insights from a systematic review of case reports"],"prefix":"10.1186","volume":"14","author":[{"given":"Yufi Aulia","family":"Azmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas F.","family":"Alkaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Muliawan","family":"Soetanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soetojo","family":"Wirjopranoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9372-2656","authenticated-orcid":false,"given":"Abdul Khairul Rizki","family":"Purba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"issue":"3","key":"2746_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000445695","volume":"97","author":"MD Sorensen","year":"2016","unstructured":"Sorensen MD, Krieger JN. Fournier\u2019s gangrene: epidemiology and outcomes in the general US population. Urol Int. 2016;97(3):249\u201359.","journal-title":"Urol Int"},{"issue":"1","key":"2746_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000490108","volume":"101","author":"SA Chernyadyev","year":"2018","unstructured":"Chernyadyev SA, Ufimtseva MA, Vishnevskaya IF, Bochkarev YM, Ushakov AA, Beresneva TA, et al. Fournier\u2019s gangrene: literature review and clinical cases. Urol Int. 2018;101(1):91\u20137.","journal-title":"Urol Int"},{"issue":"36","key":"2746_CR3","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray KSA. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Hear J. 2021;42(36):3599\u2013726.","journal-title":"Eur Hear J"},{"issue":"8","key":"2746_CR4","first-page":"e27773","volume":"14","author":"T Chowdhury","year":"2022","unstructured":"Chowdhury T, Gousy N, Bellamkonda A, Dutta J, Zaman CF, Zakia UB, Tasha T, Dutta P, Deb Roy P, Gomez AMMA. Fournier\u2019s gangrene: a coexistence or consanguinity of SGLT-2 inhibitor therapy. Cureus. 2022;14(8):e27773.","journal-title":"Cureus"},{"issue":"2","key":"2746_CR5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/dom.13900","volume":"22","author":"GA Silverii","year":"2020","unstructured":"Silverii GA, Dicembrini I, Monami MME. Fournier\u2019s gangrene and sodium-glucose co-transporter-2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2020;22(2):272\u20135.","journal-title":"Diabetes Obes Metab"},{"issue":"April","key":"2746_CR6","first-page":"1","volume":"11","author":"H Liu","year":"2024","unstructured":"Liu H. Case literature analysis of Fournier\u2019s gangrene caused by sodium-glucose protein-2 inhibitors. Front Med. 2024;11(April):1\u20136.","journal-title":"Front Med"},{"issue":"11","key":"2746_CR7","doi-asserted-by":"publisher","first-page":"764","DOI":"10.7326\/M19-0085","volume":"170","author":"SJ Bersoff-Matcha","year":"2019","unstructured":"Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter CCW. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med. 2019;170(11):764\u20139.","journal-title":"Ann Intern Med"},{"issue":"5","key":"2746_CR8","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3390\/medicina60050837","volume":"60","author":"IM Suciu","year":"2024","unstructured":"Suciu IM, Grelu\u0219 A, Cozlac AR, Suciu BS, Stoica S, Luca S, et al. Fournier\u2019s gangrene as an adverse event following treatment with sodium glucose cotransporter 2 inhibitors. Medicina. 2024;60(5):837.","journal-title":"Medicina."},{"issue":"11","key":"2746_CR9","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1001\/jamainternmed.2019.2813","volume":"179","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Patorno E. Association of sodium-glucose cotransporter 2 inhibitor treatment with risk of hospitalization for fournier gangrene among men. JAMA Intern Med. 2019;179(11):1587\u201390. https:\/\/doi.org\/10.1001\/jamainternmed.2019.2813.","journal-title":"JAMA Intern Med"},{"key":"2746_CR10","doi-asserted-by":"publisher","first-page":"6869","DOI":"10.2147\/IDR.S390008","volume":"15","author":"KF Zhang","year":"2022","unstructured":"Zhang KF, Shi CX, Chen SY, Wei W. Progress in multidisciplinary treatment of fournier\u2019s gangrene. Infect Drug Resist. 2022;15:6869\u201380. https:\/\/www.tandfonline.com\/doi\/abs\/10.2147\/IDR.S390008.","journal-title":"Infect Drug Resist."},{"issue":"970","key":"2746_CR11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1136\/pgmj.2005.042069","volume":"82","author":"A Thwaini","year":"2006","unstructured":"Thwaini A, Khan A, Malik A, Cherian J, Barua J, Shergill I, et al. Fournier\u2019s gangrene and its emergency management. Postgrad Med J. 2006;82(970):516\u20139.","journal-title":"Postgrad Med J"},{"key":"2746_CR12","unstructured":"Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu, R Currie M, Qureshi R, Mattis P, Lisy K MPF, et al. Checklist for Case Reports. Joanna Briggs Inst Crit Apprais tools. 2016:1\u20134. Available from: https:\/\/joannabriggs.org\/ebp\/critical_appraisal_tools%0Ahttps:\/\/jbi.global\/critical-appraisal-tools%0Ahttp:\/\/joannabriggs.org\/assets\/docs\/critical-appraisal-tools\/JBI_Critical_Appraisal-Checklist_for_Case_Reports2017.pdf."},{"issue":"4","key":"2746_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3109\/19390211.2013.830679","volume":"10","author":"JJ Gagnier","year":"2013","unstructured":"Gagnier JJ, Kienle G, Altman DG, Moher D, Sox HRD. The CARE guidelines: consensus-based clinical case report guideline development. J Diet Suppl. 2013;10(4):381\u201390.","journal-title":"J Diet Suppl"},{"issue":"9","key":"2746_CR14","first-page":"e29264","volume":"14","author":"T Jahir","year":"2022","unstructured":"Jahir T, Hossain S, Bagum M, Saidi A, Risal RSM. A Rare but Life-Threatening Case of Fournier\u2019s Gangrene Caused by Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor, Empagliflozin. Cureus. 2022;14(9):e29264.","journal-title":"Cureus"},{"issue":"39","key":"2746_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2021.101834","volume":"5","author":"E Vargo","year":"2021","unstructured":"Vargo E, Leone G, Barat O, Yunker APN. A case of Fournier\u2019s gangrene following a large-volume hydrocelectomy in a diabetic patient managed with SGLT-2 inhibitor therapy. Urol Case Rep. 2021;5(39): 101834.","journal-title":"Urol Case Rep"},{"issue":"11","key":"2746_CR16","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/dme.13508","volume":"34","author":"S Kumar","year":"2017","unstructured":"Kumar S, Costello AJCP. Fournier\u2019s gangrene in a man on empagliflozin for treatment of Type 2 diabetes. Diabet Med. 2017;34(11):1646\u20138.","journal-title":"Diabet Med"},{"issue":"5","key":"2746_CR17","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/1753-0407.12896","volume":"11","author":"CE Onder","year":"2019","unstructured":"Onder CE, Gursoy K, Kuskonmaz SM, Kocer U, Culha C. Fournier\u2019s gangrene in a patient on dapagliflozin treatment for type 2 diabetes. J Diabetes. 2019;11(5):348\u201350.","journal-title":"J Diabetes"},{"issue":"7","key":"2746_CR18","first-page":"e5173","volume":"11","author":"G Elshimy","year":"2019","unstructured":"Elshimy G, Correa R, Alsayed MJS. Early presentation of a rare complication of sodium-glucose cotransporter-2 inhibitors 10 days after initiation: case report and literature review. Cureus. 2019;11(7):e5173.","journal-title":"Cureus"},{"issue":"21","key":"2746_CR19","first-page":"e920115","volume":"24","author":"A Elbeddini","year":"2020","unstructured":"Elbeddini A, Gallinger J, Davey M, Brassard S, Gazarin M, Plourde FAA. A case of fournier\u2019s gangrene in a patient taking canagliflozin for the treatment of type II diabetes mellitus. Am J Case Rep. 2020;24(21):e920115.","journal-title":"Am J Case Rep"},{"issue":"2","key":"2746_CR20","doi-asserted-by":"publisher","first-page":"e237784","DOI":"10.1136\/bcr-2020-237784","volume":"14","author":"A Elbeddini","year":"2021","unstructured":"Elbeddini A, Tayefehchamani Y, Davey M, Gallinger J, Hooda N, Aly A, Erickson DLS. Fournier\u2019s gangrene with dapagliflozin in a rural hospital: a case report. BMJ Case Rep. 2021;14(2):e237784.","journal-title":"BMJ Case Rep"},{"key":"2746_CR21","doi-asserted-by":"publisher","first-page":"e921536","DOI":"10.12659\/AJCR.921536","volume":"21","author":"K Kasbawala","year":"2020","unstructured":"Kasbawala K, Stamatiades GAMS. Fournier\u2019s gangrene and diabetic ketoacidosis associated with sodium glucose co-transporter 2 (SGLT2) inhibitors: life-threatening complications. Am J Case Rep. 2020;21:e921536.","journal-title":"Am J Case Rep"},{"key":"2746_CR22","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.ijscr.2020.11.100","volume":"77","author":"L Elleg\u00e5rd","year":"2020","unstructured":"Elleg\u00e5rd L, Prytz M. Fournier\u2019s gangrene under SGLT-2 inhibitor therapy: a literature review and case report. Int J Surg Case Rep. 2020;77:692\u20134.","journal-title":"Int J Surg Case Rep"},{"issue":"2","key":"2746_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.mjafi.2020.08.013","volume":"79","author":"S Vadi","year":"2023","unstructured":"Vadi S, Ismail AKD. Fournier\u2019s gangrene and diabetic ketoacidosis with lower-than-anticipated glucose levels associated with SGLT-2 inhibitor: a double trouble. Med J Armed Forces India. 2023;79(2):225\u20138.","journal-title":"Med J Armed Forces India"},{"issue":"1","key":"2746_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40800-019-0105-8","volume":"6","author":"Y Nagano","year":"2019","unstructured":"Nagano Y, Yakame NK, Aoki H, Yamakawa TKN. Fournier\u2019s gangrene in a patient with type 2 diabetes mellitus treated with empagliflozin: a case report. Drug Saf Case Rep. 2019;6(1):11.","journal-title":"Drug Saf Case Rep"},{"issue":"9","key":"2746_CR25","first-page":"e5778","volume":"26","author":"S Rodler","year":"2019","unstructured":"Rodler S, Weig T, Finkenzeller C, Stief CSM. Fournier\u00b4s gangrene under sodium-glucose cotransporter 2 inhibitor therapy as a life-threatening adverse event: a case report and review of the literature. Cureus. 2019;26(9):e5778.","journal-title":"Cureus"},{"key":"2746_CR26","unstructured":"Cecilia-Chi W, Lim-Tio S. Fournier\u2019s syndrome: a life-threatening complication of SGLT2 inhibition in poorly controlled diabetes mellitus. Joint Annual Scientific Meeting of the Australian Diabetes Educators Association (ADEA) and Australian Diabetes. Westmead: Westmead Hospital; 2016. https:\/\/ads-adea-2016.m.asnevents.com.au\/schedule\/session\/9239\/abstract\/36604."},{"key":"2746_CR27","unstructured":"Omer T, Dharan SS, Adler A. SGLT-2 inhibitor Dapagliflozin and Fournier\u2019s gangrene A life-threatening severe adverse effect. Conference Paper Diabetes UK 2018. 2019. London: England. https:\/\/www.researchgate.net\/publication\/332211704_SGLT2_and_Fournier's_gangrene_-_a_life_threatening_adverse_effect."},{"issue":"26","key":"2746_CR28","doi-asserted-by":"publisher","first-page":"100943","DOI":"10.1016\/j.eucr.2019.100943","volume":"9","author":"A Joury","year":"2019","unstructured":"Joury A, Mahendra A, DA Alshehri M. Extensive necrotizing fasciitis from Fournier\u2019s gangrene. Urol Case Rep. 2019;9(26):100943.","journal-title":"Urol Case Rep"},{"key":"2746_CR29","doi-asserted-by":"publisher","first-page":"3695101","DOI":"10.1155\/2020\/3695101","volume":"2020","author":"Y Hu","year":"2020","unstructured":"Hu Y, Bai Z, Tang Y, Liu R, Zhao B, Gong J, et al. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a pharmacovigilance study with data from the U.S. FDA adverse event reporting system. J Diabetes Res. 2020;2020:3695101.","journal-title":"J Diabetes Res."},{"key":"2746_CR30","doi-asserted-by":"publisher","unstructured":"Sykes JE, Westropp JL. Bacterial Infections of the Genitourinary Tract. Canine and Feline Infectious Diseases. Chapter 89 Section 5. 2014. p. 871\u2013885. https:\/\/doi.org\/10.1016\/B978-1-4377-0795-3.00089-2, https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7151908\/.","DOI":"10.1016\/B978-1-4377-0795-3.00089-2"},{"issue":"23","key":"2746_CR31","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1056\/NEJMra1600673","volume":"377","author":"DLBA Stevens","year":"2017","unstructured":"Stevens DLBA. Necrotizing soft-tissue infections. N Engl J Med. 2017;377(23):2253\u201365.","journal-title":"N Engl J Med"},{"issue":"92","key":"2746_CR32","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ijid.2019.12.030","volume":"1","author":"AE El-Qushayri","year":"2020","unstructured":"El-Qushayri AE, Khalaf KM, Dahy A, Mahmoud AR, Benmelouka AY, Ghozy S, et al. Fournier\u2019s gangrene mortality: a 17-year systematic review and meta-analysis. Int J Infect Dis. 2020;1(92):218\u201325. https:\/\/doi.org\/10.1016\/j.ijid.2019.12.030.","journal-title":"Int J Infect Dis."},{"issue":"10","key":"2746_CR33","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1007\/s00125-018-4663-6","volume":"61","author":"BC Lupsa","year":"2018","unstructured":"Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia. 2018;61(10):2118\u201325. https:\/\/doi.org\/10.1007\/s00125-018-4663-6.","journal-title":"Diabetologia."},{"key":"2746_CR34","unstructured":"FDA. FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. 2024. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes#:~:text=This adverse event is a,the bottom of this page."},{"issue":"2023","key":"2746_CR35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.58496\/MJAIH\/2023\/013","volume":"22","author":"H Omotunde","year":"2023","unstructured":"Omotunde H, Mouhamed M. The modern impact of artificial intelligence systems in healthcare: a concise analysis. Mesopotamian J Artif Intell Healthc. 2023;22(2023):66\u201370.","journal-title":"Mesopotamian J Artif Intell Healthc"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-024-02746-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-024-02746-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-024-02746-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T11:49:24Z","timestamp":1737978564000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-024-02746-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2746"],"URL":"https:\/\/doi.org\/10.1186\/s13643-024-02746-3","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}